These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 9555968)
21. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Mousa SA; Khurana S; Forsythe MS Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688 [TBL] [Abstract][Full Text] [Related]
22. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro. Hamilton SF; Miller MW; Thompson CA; Dale GL J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176 [TBL] [Abstract][Full Text] [Related]
23. Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets. Sheu JR; Kan YC; Hung WC; Ko WC; Yen MH Thromb Res; 1997 Nov; 88(3):259-70. PubMed ID: 9526946 [TBL] [Abstract][Full Text] [Related]
24. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Schneider DJ; Taatjes DJ; Sobel BE Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364 [TBL] [Abstract][Full Text] [Related]
25. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088 [TBL] [Abstract][Full Text] [Related]
26. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Smith JW; Steinhubl SR; Lincoff AM; Coleman JC; Lee TT; Hillman RS; Coller BS Circulation; 1999 Feb; 99(5):620-5. PubMed ID: 9950658 [TBL] [Abstract][Full Text] [Related]
27. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852 [TBL] [Abstract][Full Text] [Related]
28. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alpha IIb beta 3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Tsao PW; Forsythe MS; Mousa SA Thromb Res; 1997 Oct; 88(2):137-46. PubMed ID: 9361367 [TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis. Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529 [TBL] [Abstract][Full Text] [Related]
30. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Dyke CM Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236 [TBL] [Abstract][Full Text] [Related]
31. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes. Keating FK; Whitaker DA; Sobel BE; Schneider DJ Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562 [TBL] [Abstract][Full Text] [Related]
33. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation. Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373 [TBL] [Abstract][Full Text] [Related]
34. Effect of nitric oxide gas on platelets during open heart operations. Mellgren K; Mellgren G; Lundin S; Wennmalm A; Wadenvik H Ann Thorac Surg; 1998 May; 65(5):1335-41. PubMed ID: 9594863 [TBL] [Abstract][Full Text] [Related]
35. Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist. Hayashi Y; Katada J; Sato Y; Igarashi K; Takiguchi Y; Harada T; Muramatsu M; Yasuda E; Uno I Bioorg Med Chem; 1998 Mar; 6(3):355-64. PubMed ID: 9568289 [TBL] [Abstract][Full Text] [Related]
40. Functional relevance of the expression of ligand-induced binding sites in the response to platelet GP IIb/IIIa antagonists in vivo. Murphy NP; Pratico D; Fitzgerald DJ J Pharmacol Exp Ther; 1998 Aug; 286(2):945-51. PubMed ID: 9694954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]